183 related articles for article (PubMed ID: 10063998)
1. Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice.
Connelly S; Andrews JL; Gallo-Penn AM; Tagliavacca L; Kaufman RJ; Kaleko M
Thromb Haemost; 1999 Feb; 81(2):234-9. PubMed ID: 10063998
[TBL] [Abstract][Full Text] [Related]
2. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
[TBL] [Abstract][Full Text] [Related]
3. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.
Gallo-Penn AM; Shirley PS; Andrews JL; Kayda DB; Pinkstaff AM; Kaloss M; Tinlin S; Cameron C; Notley C; Hough C; Lillicrap D; Kaleko M; Connelly S
Hum Gene Ther; 1999 Jul; 10(11):1791-802. PubMed ID: 10446919
[TBL] [Abstract][Full Text] [Related]
4. In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice.
Bristol JA; Shirley P; Idamakanti N; Kaleko M; Connelly S
Mol Ther; 2000 Sep; 2(3):223-32. PubMed ID: 10985953
[TBL] [Abstract][Full Text] [Related]
5. Efficient adenoviral vector transduction and expression of functional human factor VIII in cultured primary human hepatocytes.
Andrews JL; Weaver L; Kaleko M; Connelly S
Haemophilia; 1999 May; 5(3):160-8. PubMed ID: 10444282
[TBL] [Abstract][Full Text] [Related]
6. Development and application of a minimal-adenoviral vector system for gene therapy of hemophilia A.
Zhang WW; Josephs SF; Zhou J; Fang X; Alemany R; Balagué C; Dai Y; Ayares D; Prokopenko E; Lou YC; Sethi E; Hubert-Leslie D; Kennedy M; Ruiz L; Rockow-Magnone S
Thromb Haemost; 1999 Aug; 82(2):562-71. PubMed ID: 10605752
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
8. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon.
Liu L; Mah C; Fletcher BS
Mol Ther; 2006 May; 13(5):1006-15. PubMed ID: 16464640
[TBL] [Abstract][Full Text] [Related]
9. Preclinical gene therapy studies for hemophilia using adenoviral vectors.
Thorrez L; VandenDriessche T; Collen D; Chuah MK
Semin Thromb Hemost; 2004 Apr; 30(2):173-83. PubMed ID: 15118929
[TBL] [Abstract][Full Text] [Related]
10. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice.
Ishiwata A; Mimuro J; Mizukami H; Kashiwakura Y; Takano K; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
J Gene Med; 2009 Nov; 11(11):1020-9. PubMed ID: 19757487
[TBL] [Abstract][Full Text] [Related]
11. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
[TBL] [Abstract][Full Text] [Related]
12. Expression of human coagulation factor VIII in adipocytes transduced with the simian immunodeficiency virus agmTYO1-based vector for hemophilia A gene therapy.
Ogata K; Mimuro J; Kikuchi J; Tabata T; Ueda Y; Naito M; Madoiwa S; Takano K; Hasegawa M; Ozawa K; Sakata Y
Gene Ther; 2004 Feb; 11(3):253-9. PubMed ID: 14737084
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for hemophilia A.
Connelly S; Kaleko M
Thromb Haemost; 1997 Jul; 78(1):31-6. PubMed ID: 9198123
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for hemophilia.
Lynch CM
Curr Opin Mol Ther; 1999 Aug; 1(4):493-9. PubMed ID: 11713765
[TBL] [Abstract][Full Text] [Related]
15. Sustained expression of Epstein-Barr virus episomal vector mediated factor VIII in vivo following muscle electroporation.
Mei WH; Qian GX; Zhang XQ; Zhang P; Lu J
Haemophilia; 2006 May; 12(3):271-9. PubMed ID: 16643213
[TBL] [Abstract][Full Text] [Related]
16. Enhanced plasma factor VIII activity in mice via cysteine mutation using dual vectors.
Zhu F; Liu Z; Miao J; Qu H; Chi X
Sci China Life Sci; 2012 Jun; 55(6):521-6. PubMed ID: 22744182
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for hemophilia.
Chuah MK; Collen D; VandenDriessche T
J Gene Med; 2001; 3(1):3-20. PubMed ID: 11269333
[TBL] [Abstract][Full Text] [Related]
18. Analysis of factor VIII mediated suppression of lentiviral vector titres.
Radcliffe PA; Sion CJ; Wilkes FJ; Custard EJ; Beard GL; Kingsman SM; Mitrophanous KA
Gene Ther; 2008 Feb; 15(4):289-97. PubMed ID: 18046428
[TBL] [Abstract][Full Text] [Related]
19. Clinical gene transfer studies for hemophilia A.
Chuah MK; Collen D; VandenDriessche T
Semin Thromb Hemost; 2004 Apr; 30(2):249-56. PubMed ID: 15118936
[TBL] [Abstract][Full Text] [Related]
20. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction.
Tiede A; Eder M; von Depka M; Battmer K; Luther S; Kiem HP; Ganser A; Scherr M
Gene Ther; 2003 Oct; 10(22):1917-25. PubMed ID: 14502221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
